In the MET samples, we found differences only within CD56+ and CD45+ cell counts: CD56+ was lower in those cases, where the metastasis was present since the diagnosis of CRC (Stage I–II vs. IV: p = 0.0208, Stage I–II vs. III: p = 0.1056; Figure 4A); similarly, CD45+ was marginally higher in Stage IV CRC (Stage III vs. IV: p = 0.0820; Figure 4B). This evidence concerns the gene PTPRC and colorectal carcinoma.